Data Insights

ABBV-101 by AbbVie for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Anaplastic Large Cell Lymphoma (ALCL)

Data Insights

ABBV-101 by AbbVie for Mantle Cell Lymphoma: Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Mantle Cell Lymphoma

Data Insights

ABBV-101 by AbbVie for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Primary Mediastinal B-Cell Lymphoma

Data Insights

ABBV-101 by AbbVie for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Splenic Marginal Zone B-Cell Lymphoma

Data Insights

ABBV-101 by AbbVie for Non-Hodgkin Lymphoma: Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Non-Hodgkin Lymphoma

Data Insights

ABBV-101 by AbbVie for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

ABBV-101 by AbbVie for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Nodal Marginal Zone B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Nodal Marginal Zone B-Cell Lymphoma

Data Insights

ABBV-101 by AbbVie for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Diffuse Large B-Cell Lymphoma

Data Insights

ABBV-101 by AbbVie for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)

Data Insights

ABBV-101 by AbbVie for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

ABBV-101 by AbbVie for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

ABBV-101 by AbbVie for Hematological Tumor: Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Hematological Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Hematological Tumor

Data Insights

ABBV-101 by AbbVie for Follicular Lymphoma: Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Follicular Lymphoma